Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Price history
Loading EOCN daily closes…
Loading price history…
Pipeline assets
Aramchol
Stage not disclosed · Active
Target SCD1
Indications
NASH/MASH and fibrosis(Stage not disclosed)
Status note Excerpts are forward-looking boilerplate only: no stage, target, modality, trial status or dated catalyst stated. Named indication: NASH/MASH and fibrosis (mentioned in context of potential label expansion). Excerpts too thin to judge beyond the name and indication.
Per-asset detail extracted from the 20-F filed 2026-03-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.